Current Influenza Antiviral Drug Strategy Limitations and Future Development of both Preventative and Intervention Antiviral Therapies


如何引用文章

全文:

作者简介

Fahim Ahmad

Department of Infectious Disease, Scientific Platform Division, Southern Research

编辑信件的主要联系方式.
Email: info@benthamscience.net

参考

  1. Palese P, Shaw ML. Orthomyxoviridae: The viruses and their replication. In: Fields Virology. 5 th . Philadelphia: Lippincott-Raven Press 2007; pp. 1647-90.
  2. Centers for Disease Control Prevention. 2011. Available from: http://www.cdc.gov/flu/about/disease/index.htm
  3. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188(1): 57-61. doi: 10.1086/375799 PMID: 12825171
  4. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325(5937): 197-201. doi: 10.1126/science.1176225 PMID: 19465683
  5. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295(8): 891-4. doi: 10.1001/jama.295.8.joc60020 PMID: 16456087
  6. Fang Q, Wang D. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir. Biosaf Heal 2020; 2(2): 64-70. doi: 10.1016/j.bsheal.2020.04.004

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bentham Science Publishers, 2024